Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.45
NAS:KERX's Cash-to-Debt is ranked lower than
88% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. NAS:KERX: 0.45 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:KERX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45  Med: No Debt Max: No Debt
Current: 0.45
Equity-to-Asset -0.06
NAS:KERX's Equity-to-Asset is ranked lower than
92% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. NAS:KERX: -0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:KERX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06  Med: 0.71 Max: 0.9
Current: -0.06
-0.06
0.9
Piotroski F-Score: 3
Altman Z-Score: -7.62
Beneish M-Score: -5.29
WACC vs ROIC
27.14%
-449.68%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -383.84
NAS:KERX's Operating Margin % is ranked lower than
66% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. NAS:KERX: -383.84 )
Ranked among companies with meaningful Operating Margin % only.
NAS:KERX' s Operating Margin % Range Over the Past 10 Years
Min: -9016.3  Med: -742.26 Max: 38.97
Current: -383.84
-9016.3
38.97
Net Margin % -503.69
NAS:KERX's Net Margin % is ranked lower than
70% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. NAS:KERX: -503.69 )
Ranked among companies with meaningful Net Margin % only.
NAS:KERX' s Net Margin % Range Over the Past 10 Years
Min: -8585.51  Med: -783.89 Max: 41.62
Current: -503.69
-8585.51
41.62
ROE % -383.79
NAS:KERX's ROE % is ranked lower than
95% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. NAS:KERX: -383.79 )
Ranked among companies with meaningful ROE % only.
NAS:KERX' s ROE % Range Over the Past 10 Years
Min: -409.71  Med: -131.46 Max: 68.51
Current: -383.79
-409.71
68.51
ROA % -79.75
NAS:KERX's ROA % is ranked lower than
79% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:KERX: -79.75 )
Ranked among companies with meaningful ROA % only.
NAS:KERX' s ROA % Range Over the Past 10 Years
Min: -135.67  Med: -77.46 Max: 31.09
Current: -79.75
-135.67
31.09
ROC (Joel Greenblatt) % -350.18
NAS:KERX's ROC (Joel Greenblatt) % is ranked higher than
54% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. NAS:KERX: -350.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:KERX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46369.35  Med: -7580 Max: 7114.49
Current: -350.18
-46369.35
7114.49
3-Year Revenue Growth Rate 52.00
NAS:KERX's 3-Year Revenue Growth Rate is ranked higher than
87% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. NAS:KERX: 52.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:KERX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 237.3
Current: 52
0
237.3
3-Year EBITDA Growth Rate 27.00
NAS:KERX's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 0.20 vs. NAS:KERX: 27.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:KERX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.1  Med: 17.7 Max: 70.9
Current: 27
-45.1
70.9
3-Year EPS without NRI Growth Rate 37.90
NAS:KERX's 3-Year EPS without NRI Growth Rate is ranked higher than
86% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:KERX: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:KERX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.7  Med: 18 Max: 60
Current: 37.9
-44.7
60
GuruFocus has detected 3 Warning Signs with Keryx Biopharmaceuticals Inc $NAS:KERX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:KERX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

KERX Guru Trades in Q1 2016

Joel Greenblatt 25,457 sh (New)
Chuck Royce 451,725 sh (+32.19%)
David Abrams 5,719,176 sh (+3.99%)
Seth Klarman 25,791,678 sh (unchged)
Paul Tudor Jones 30,106 sh (-32.49%)
» More
Q2 2016

KERX Guru Trades in Q2 2016

Joel Greenblatt 77,976 sh (+206.30%)
Paul Tudor Jones 30,687 sh (+1.93%)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Chuck Royce 451,725 sh (unchged)
» More
Q3 2016

KERX Guru Trades in Q3 2016

Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Chuck Royce 317,725 sh (-29.66%)
» More
Q4 2016

KERX Guru Trades in Q4 2016

Joel Greenblatt 76,726 sh (New)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Chuck Royce 256,725 sh (-19.20%)
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI, NAS:BMRN » details
Traded in other countries:KYX.Germany,
Keryx Biopharmaceuticals Inc is a biopharmaceutical company focused on therapies for patients with renal disease. Its first product is the AuryxiaTM (ferric citrate), an oral, absorbable iron-based compound.

Keryx Biopharmaceuticals acquires and develops novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx commenced operations in 1999 and has three key products in clinical trials for kidney disease and various cancers. The company acquired a renal disease-related drug candidate, Zerenex, and an approved diagnostic product, Accumin, in 2006.

Ratios

vs
industry
vs
history
PS Ratio 19.73
KERX's PS Ratio is ranked lower than
57% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. KERX: 19.73 )
Ranked among companies with meaningful PS Ratio only.
KERX' s PS Ratio Range Over the Past 10 Years
Min: 1.18  Med: 57.83 Max: 2228
Current: 19.73
1.18
2228
Current Ratio 6.17
KERX's Current Ratio is ranked higher than
65% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. KERX: 6.17 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.03 Max: 35.68
Current: 6.17
1.88
35.68
Quick Ratio 5.58
KERX's Quick Ratio is ranked higher than
63% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. KERX: 5.58 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 5.74 Max: 35.68
Current: 5.58
1.88
35.68
Days Inventory 288.38
KERX's Days Inventory is ranked lower than
84% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. KERX: 288.38 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 244.72  Med: 1365.48 Max: 2886.82
Current: 288.38
244.72
2886.82
Days Sales Outstanding 59.75
KERX's Days Sales Outstanding is ranked lower than
51% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. KERX: 59.75 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 98.47
Current: 59.75
0.51
98.47
Days Payable 19.96
KERX's Days Payable is ranked lower than
80% of the 353 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. KERX: 19.96 )
Ranked among companies with meaningful Days Payable only.
KERX' s Days Payable Range Over the Past 10 Years
Min: 19.96  Med: 463.34 Max: 42743.3
Current: 19.96
19.96
42743.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
KERX's 3-Year Average Share Buyback Ratio is ranked higher than
59% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. KERX: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -11.9 Max: -6.3
Current: -8.6
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.34
KERX's Price-to-Median-PS-Value is ranked higher than
89% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. KERX: 0.34 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KERX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 2.01 Max: 17.73
Current: 0.34
0.08
17.73
Earnings Yield (Greenblatt) % -16.23
KERX's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. KERX: -16.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KERX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17.36  Med: 191.2 Max: 27616.5
Current: -16.23
-17.36
27616.5

More Statistics

Revenue (TTM) (Mil) $31.98
EPS (TTM) $ -1.52
Beta3.56
Short Percentage of Float26.35%
52-Week Range $4.03 - 7.80
Shares Outstanding (Mil)107.67

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 63 151 271
EPS ($) -0.18 0.32 0.89
EPS without NRI ($) -0.18 0.32 0.89
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:KERX

Headlines

Articles On GuruFocus.com
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
Is Seth Klarman right about Keryx Inc.? Jun 25 2015 
Seth Klarman Buys Pioneer Natural Resources, SunEdison Semiconductor Ltd, Atara Biotherapeutics Inc, May 15 2015 
Analysts Positive on Keryx Biopharmaceuticals, Inc. Despite Weak Prescription Data May 05 2015 

More From Other Websites
Keryx's Auryxia Added to Largest Medicare Part D Plan Mar 22 2017
Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Mar 21 2017
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan... Mar 20 2017
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat Mar 16 2017
Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets Mar 09 2017
Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application... Mar 08 2017
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
KERYX BIOPHARMACEUTICALS INC Financials Mar 07 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for... Mar 07 2017
Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat Mar 02 2017
Edited Transcript of KERX earnings conference call or presentation 1-Mar-17 1:00pm GMT Mar 01 2017
Keryx (KERX) Posts Wider-than-Expected Loss in Q4 Mar 01 2017
Keryx Biopharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Mar 01 2017
Keryx Biopharma reports 4Q loss Mar 01 2017
Keryx Biopharma reports 4Q loss Mar 01 2017
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 01 2017
Q4 2016 Keryx Biopharmaceuticals Inc Earnings Release - Before Market Open Mar 01 2017
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Should You Sell Keryx Biopharmaceuticals (KERX) Before Earnings? Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)